CN110709400A - Pol1抑制剂的新型晶体形式 - Google Patents

Pol1抑制剂的新型晶体形式 Download PDF

Info

Publication number
CN110709400A
CN110709400A CN201880035566.4A CN201880035566A CN110709400A CN 110709400 A CN110709400 A CN 110709400A CN 201880035566 A CN201880035566 A CN 201880035566A CN 110709400 A CN110709400 A CN 110709400A
Authority
CN
China
Prior art keywords
crystalline form
cancer
crystalline
compound
crystalline forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880035566.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·哈达彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pimera Inc
Original Assignee
Pimera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pimera Inc filed Critical Pimera Inc
Priority to CN202210899067.8A priority Critical patent/CN115583948A/zh
Publication of CN110709400A publication Critical patent/CN110709400A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201880035566.4A 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式 Pending CN110709400A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210899067.8A CN115583948A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762477746P 2017-03-28 2017-03-28
US62/477,746 2017-03-28
US201762491635P 2017-04-28 2017-04-28
US62/491,635 2017-04-28
PCT/US2018/024898 WO2018183540A1 (en) 2017-03-28 2018-03-28 Novel crystal forms of a pol1 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210899067.8A Division CN115583948A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式

Publications (1)

Publication Number Publication Date
CN110709400A true CN110709400A (zh) 2020-01-17

Family

ID=63676829

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880035566.4A Pending CN110709400A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式
CN202210899067.8A Pending CN115583948A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210899067.8A Pending CN115583948A (zh) 2017-03-28 2018-03-28 Pol1抑制剂的新型晶体形式

Country Status (7)

Country Link
US (2) US11912706B2 (enExample)
EP (1) EP3601286A4 (enExample)
JP (3) JP2020512975A (enExample)
CN (2) CN110709400A (enExample)
BR (1) BR112019020058A2 (enExample)
CA (1) CA3057741A1 (enExample)
WO (1) WO2018183540A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
CN110709400A (zh) 2017-03-28 2020-01-17 皮梅拉股份有限公司 Pol1抑制剂的新型晶体形式

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160257678A1 (en) * 2015-03-04 2016-09-08 Pimera, Inc. Novel compositions, uses and methods for making them
CN106349244A (zh) * 2015-07-13 2017-01-25 首都医科大学 苯并咪唑并喹唑啉二甲氧苯氧乙酰-AA-OBzl，其合成，活性和应用
CN106459068A (zh) * 2014-05-09 2017-02-22 皮梅拉股份有限公司 新组合物、用途和制备它们的方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1042801A (en) 1909-10-28 1912-10-29 Isidor Kitsee Protecting kinematographic films.
NL7709746A (nl) 1976-09-09 1978-03-13 Hoechst Ag Werkwijze ter bereiding van benzimidazo-(1,2-a)-chi- nolinen.
DE2929414A1 (de) 1979-07-20 1981-02-05 Hoechst Ag Pyrimido- eckige klammer auf 5',4' zu 5,6 eckige klammer zu -pyrido- eckige klammer auf 1,2-a eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung und deren verwendung
DE3502689A1 (de) 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt Elektrophotographisches aufzeichnungsmaterial
DE19509043A1 (de) 1995-03-03 1996-09-05 Bayer Ag Cyanierung von Doppelbindungssystemen
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
HUP0302925A3 (en) 2000-10-03 2004-10-28 Bristol Myers Squibb Co Amino-substituted tetracyclic compouds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US7354916B2 (en) 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
WO2004091504A2 (en) 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
EP1802306A2 (en) 2004-09-17 2007-07-04 Cylene Pharmaceuticals, Inc. Quinolone analog as cell proliferation inhibitors
EP1874731A4 (en) 2005-04-15 2009-08-05 Cylene Pharmaceuticals Inc CHINOBENZOXAZINANALOGA AND METHOD FOR THE APPLICATION
WO2007019295A1 (en) 2005-08-05 2007-02-15 Cylene Pharmaceuticals, Inc. Methods of preparing quinolone analogs
WO2007038215A1 (en) 2005-09-22 2007-04-05 Incyte Corporation Tetracyclic inhibitors of janus kinases
US8142909B2 (en) 2006-02-10 2012-03-27 Universal Display Corporation Blue phosphorescent imidazophenanthridine materials
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
WO2008060693A2 (en) 2006-05-17 2008-05-22 Cylene Pharmaceuticals, Inc. Tetracyclic imidazole analogs
CA2701630C (en) 2007-10-05 2016-10-25 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
ATE542813T1 (de) 2008-08-06 2012-02-15 Pfizer 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
US8368062B2 (en) 2008-11-03 2013-02-05 Lg Chem, Ltd. Nitrogen-containing heterocyclic compound and organic electronic device using the same
US8124770B2 (en) 2009-04-01 2012-02-28 Beatriz Zayas Fluorescent cellular markers
CN101781312B (zh) 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 一种吲哚衍生物的合成方法
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
KR101567610B1 (ko) 2010-11-04 2015-11-09 주식회사 엘지화학 신규한 질소 함유 헤테로환 화합물 및 이를 이용한 유기 전자 소자
BR112014008727A2 (pt) 2011-10-21 2017-04-25 Glaxosmithkline Llc composto, composição farmacêutica, uso do composto ou sal, métodos para o tratamento de e/ou a prevenção de uma doença ou condição, para a intensificação da resposta imune em um indivíduo, e para regular por regulação positiva uma resposta imune a jak/stat em um indivíduo
KR101561730B1 (ko) 2012-02-06 2015-10-22 주식회사 엘지화학 질소원소를 함유한 헤테로고리 유도체 및 이를 이용한 유기 전자 소자
EP3074391B1 (en) 2013-11-28 2019-07-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
CN119185322A (zh) 2015-11-20 2024-12-27 生华生物科技股份有限公司 用于治疗癌症的四环喹诺酮类似物组合疗法
CN110709400A (zh) 2017-03-28 2020-01-17 皮梅拉股份有限公司 Pol1抑制剂的新型晶体形式

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106459068A (zh) * 2014-05-09 2017-02-22 皮梅拉股份有限公司 新组合物、用途和制备它们的方法
US20160257678A1 (en) * 2015-03-04 2016-09-08 Pimera, Inc. Novel compositions, uses and methods for making them
CN106349244A (zh) * 2015-07-13 2017-01-25 首都医科大学 苯并咪唑并喹唑啉二甲氧苯氧乙酰-AA-OBzl，其合成，活性和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ZANZOUL, A.A,B,C: "A benzimidazopyridoquinoxaline as promising scaffold for G-quadruplex DNA targeting", 《MEDICINAL CHEMISTRY RESEARCH》 *
韩丽萍: "RNA干扰靶向沉默polβ基因对人卵巢癌细胞增殖活性及对化疗药物敏感性的影响", 《中国肿瘤临床》 *

Also Published As

Publication number Publication date
EP3601286A1 (en) 2020-02-05
WO2018183540A1 (en) 2018-10-04
BR112019020058A2 (pt) 2020-07-14
US20250243200A1 (en) 2025-07-31
EP3601286A4 (en) 2020-09-23
US20230192694A1 (en) 2023-06-22
JP2025060702A (ja) 2025-04-10
US11912706B2 (en) 2024-02-27
JP2020512975A (ja) 2020-04-30
CN115583948A (zh) 2023-01-10
CA3057741A1 (en) 2018-10-04
JP2023126708A (ja) 2023-09-08

Similar Documents

Publication Publication Date Title
JP6506779B2 (ja) 医薬化合物
CA3032795C (en) Imidazopyridinamine phenyl derivative and use thereof
JP2025060702A (ja) Ｐｏｌ１阻害剤の新規な結晶形態
US20140057913A1 (en) Aurora kinase inhibitors and methods of making and using thereof
KR20170068597A (ko) 브로모도메인 저해제
CN101679274A (zh) 具有slp受体调节活性的酞嗪及异喹啉衍生物
US20250115555A1 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
CN112384513A (zh) Gabaa正变构调节剂化合物、其制备方法和用途
ES2539236T3 (es) Sal de ácido benzoico de Otamixaban
US20180177781A1 (en) Novel crystalline forms
HK40020743A (en) Novel crystal forms of a pol1 inhibitor
WO2023197914A1 (zh) 一种吡唑并嘧啶类化合物的新用途
CN106795153A (zh) 取代的咪唑并吡啶基‑氨基吡啶化合物的盐和多晶型
US10793554B2 (en) Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
EP4168003A2 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
CA3224122A1 (en) Erk5 degraders and uses thereof
WO2020222190A1 (en) Crystalline form of 6-[4-[1 -(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1 -yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide
WO2020222189A1 (en) Crystalline form of 6-[4-[1-(propan-2-yl)piperidin-4-yl]-1,4-diazepan-1-yl]-n-(pyrdin-4-yl)pyridine-2-carboxamide
HK1234747B (zh) 取代的咪唑并吡啶基-氨基吡啶化合物的盐和多晶型
NZ795495A (en) Aminothiazole compounds as c-Kit inhibitors
TW201247641A (en) Glycine transport inhibitor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020743

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20200117

RJ01 Rejection of invention patent application after publication